SCHEMBL20705348

SCHEMBL20705348

Cc1ncnn1CC(O)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.42
ALDH1A1 P00352 2/20 0.39
APAF1 O14727 4/20 0.35
LMNA P02545 2/20 0.35
POLB P06746 1/20 0.35
KCNH2 Q12809 1/20 0.34
HDAC1 Q13547 2/20 0.33
HDAC6 Q9UBN7 2/20 0.33
PTPRA P18433 1/20 0.33
GRIA1 P42261 2/20 0.31
GRIA2 P42262 2/20 0.31
GRIA3 P42263 2/20 0.31
GRIA4 P48058 2/20 0.31
GRIK1 P39086 1/20 0.31
GRIK2 Q13002 1/20 0.31
GRIK3 Q13003 1/20 0.31
GRIK4 Q16099 1/20 0.31
GRIK5 Q16478 1/20 0.31
HSD17B10 Q99714 1/20 0.31
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20705347 1.00 KMO (0.42) KMOALDH1A1APAF1LMNAPOLB
SCHEMBL23138139 0.82 CYP1A2 (0.39) ALDH1A1KCNH2HSD17B10SMN1; SMN2
SCHEMBL16296881 0.81 GRIA1 (0.48) KMOGRIA1GRIA2GRIA3GRIA4
SCHEMBL15156739 0.74 LMNA (0.47) KMOALDH1A1LMNAPOLBHSD17B10
SCHEMBL23989354 0.72 KCNH2 (0.38) KCNH2HTT
SCHEMBL21241149 0.69 LMNA (0.41) ALDH1A1LMNAKCNH2HSD17B10HTT
SCHEMBL21233319 0.67 RAB9A (0.44) ALDH1A1POLBHTT
SCHEMBL20703189 0.66 ALDH1A1 (0.39) KMOALDH1A1APAF1LMNAPOLB
SCHEMBL20703191 0.66 ALDH1A1 (0.39) KMOALDH1A1APAF1LMNAPOLB
SCHEMBL23118131 0.62 HSD17B10 (0.50) KMOALDH1A1LMNAPOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111356680-B Selective inhibitors of NLRP3 inflammasome 诺瑟拉有限公司 2023-11-28 CN disclosed
EP-3661921-B1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NODTHERA LTD (GB) 2023-10-18 EP disclosed
US-20210087147-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2021-03-25 US disclosed
CN-111356680-A Selective inhibitors of NLRP3inflammasome 诺瑟拉有限公司 2020-06-30 CN disclosed
EP-3661921-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME Nodthera Limited (GB) 2020-06-10 EP disclosed
WO-2019025467-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2019-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210087147-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, NOD1, NLRP1 KMO 1995/4885ALDH1A1 961/4885APAF1 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.